Roots Analysis

 The CAR-T Cell Therapy Market, 2021-2030 report features a comprehensive analysis of the current market landscape; the market is projected to be worth around USD 14 Billion, increasing at a CAGR of 28.9%, till 2030, envisions Roots Analysis. The market is anticipated to grow at a CAGR of over 28% during 2021-2030. Growth in this area is expected to be driven primarily by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of sales-based revenues. Given their ability to selectively direct a cell-mediated immune reaction against cancer cells and, thereby, offer extended periods of disease remission, several CAR-T cell therapies deliver a promising therapeutic strategy for advanced-stage cancers and are expected to reach blockbuster status. With four approved products and many investigational therapy candidates a...

 For various reasons, the demand for cell therapies is expected to increase in the coming years. Therefore, both therapy developers and contracted service providers may need to strengthen their skills and expand available capacity. In this regard, automation is expected to be a key enabler in the cell therapy manufacturing and contract services industry. Growing at an annualized rate of more than 16.5%, the  cell therapy manufacturing market is projected to reach close to USD 11 billion by 2030, according to Roots Analysis. Cell therapy manufacturers are also gradually choosing to automate various operations in the supply chain; The main goal is to achieve favorable bench-to-clinic timelines and to reduce production-related losses. Currently, the installed global capacity for cell therapy manufacturing is estimated to be spread across 1.2+ million square feet of dedicated cleanroom area distributed across various scales of operation. It has been estimated that more th...